- Home
- ASAN vs KNSA Comparison
ASAN vs KNSA Comparison
Compare ASAN & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASAN | KNSA |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.5B |
| IPO Year | 2020 | 2018 |
Fundamental Metrics
Financial Performance| Metric | ASAN | KNSA |
|---|---|---|
| Price | $5.43 | $46.96 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 7 |
| Target Price | $12.62 | ★ $55.29 |
| AVG Volume (30 Days) | ★ 5.5M | 565.9K |
| Earning Date | 03-02-2026 | 04-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 27.93 | ★ 225.00 |
| EPS | N/A | ★ 0.75 |
| Revenue | ★ $790,806,000.00 | $677,564,000.00 |
| Revenue This Year | $10.19 | $38.01 |
| Revenue Next Year | $7.91 | $17.42 |
| P/E Ratio | ★ N/A | $63.27 |
| Revenue Growth | 9.25 | ★ 60.09 |
| 52 Week Low | $5.55 | $19.42 |
| 52 Week High | $19.00 | $50.03 |
Technical Indicators
Market Signals| Indicator | ASAN | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 23.01 | 51.17 |
| Support Level | N/A | $39.96 |
| Resistance Level | $6.67 | $48.14 |
| Average True Range (ATR) | 0.37 | 1.83 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 1.13 | 45.20 |
Price Performance
Historical ComparisonAbout ASAN Asana Inc.
Asana is a work management platform that allows for increased collaboration and visibility across an organization. Delivered via a SaaS-based model, users can track progress across marketing and development initiatives, create and automate workflows, and manage IT approvals. Revenue is generated on a per-seat basis across several pricing tiers. As of fiscal 2025, the company had over 175,000 customers.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.